| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.24 | 0.1 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.096 | 0.1 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.26 | 0.1 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |